A phase Ib/II, multicenter, open-label study to evaluate the efficacy of AUY922 in combination with trastuzumab in patients with locally advanced or metasatatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-con

Cancer type: Breast cancer

Phase: I

Principal Investigator: Hatschek Thomas

Country: SE

Keywords: Sweden, HSP90 inhibitor, HER2 positivity

Status: Completed

Link to